WHAT IS ALPHA FETOPROTEIN?
Alpha fetoprotein (AFP) is a human protein produced during fetal development. It protects the embryo from the mother’s immune system and carries nutrients to rapidly growing embryonic cells via AFP receptors (AFPRs). After birth, AFP production and AFPR expression recede — and AFPRs reappear on most cancer cells and on myeloid-derived suppressor cells (MDSCs).
WHAT IS ACT-101?
ACT-101 is ACT’s recombinant human AFP, differing from natural human AFP by a single amino acid substitution at position 233 (glutamine for asparagine). It is non-glycosylated, has 16 disulfide bridges, and is now produced from an E. coli cell line developed by Absci – a generative AI company. ACT-101 was studied in Merrimack Pharmaceuticals’ Phase I and II rheumatoid arthritis clinical studies in over 300 patients, with no serious adverse events and no neutralizing antibodies at doses of up to 100 mg per week .
WHAT IS ACT-903?
ACT-903 is ACT’s lead oncology program: a protein drug conjugate (PDC) that links ACT-101 to a proprietary maytansine (chemotherapy) payload with a glutathione-sensitive linker. It targets AFPRs on cancer cells and MDSCs. In an ovarian cancer xenograft study it eliminated tumors completely with no regrowth to day 62; that study used immunodeficient mice, so the immune effect of removing MDSCs, demonstrated in syngeneic mice, remains to be demonstrated in clinical studies.
WHAT STAGE IS ACT-903 AT?
IND-enabling work is ongoing, and a Phase Ia/b multiple-ascending-dose basket study is planned, enriched to an orphan indication such as platinum-resistant ovarian cancer or testicular germ cell cancer.
WHAT IS THE PDC RATIONALE?
Because AFPRs are present on most cancers and on MDSCs but absent on normal adult cells in studies to date, attaching a potent payload to ACT-101 is designed to concentrate treatment in tumors while sparing normal tissue — and, by removing the MDSC shield, to let the immune system attack the tumor as well.WHAT ABOUT AUTOIMMUNE DISEASE?
ACT-101 is Phase II-ready in Myasthenia Gravis (FDA Orphan Drug Designation granted) and in Inflammatory Bowel Disease, and is being positioned for partnering and outlicensing. A 78-patient IBD study used wild-type AFP from human fetal tissue, not ACT-101, but demonstrated superiority to anti-TNF drugs in a preclinical TNBS model.
WHY WAS MAYTANSINE SELECTED?
Maytansine is 100–1,000 times more potent in laboratory cell-killing tests than conventional chemotherapies such as doxorubicin, and the maytansinoid class is clinically validated in approved conjugates such as Kadcyla (DM1) and Elahere (DM4). ACT-903 uses a proprietary maytansine with a glutathione-sensitive linker created for ACT.
IS ACT-101 IMMUNOGENIC?
In clinical studies in over 300 patients, no neutralizing antibodies were found. ACT-101 is immunogenic in other species as it is a recombinant human protein.